# Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

> **NCT07356245** · PHASE2 · RECRUITING · sponsor: **Jonathan Brammer** · enrollment: 44 (estimated)

## Conditions studied

- T-cell Lymphoma
- Graft Versus Host Disease
- Lymphoma, T-Cell
- Peripheral T Cell Lymphoma
- T-cell Prolymphocytic Leukemia
- Cutaneous T Cell Lymphoma
- Adult T-cell Leukemia/Lymphoma
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Ruxolitinib
- **PROCEDURE:** Positron emission tomography-computed tomography
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT07356245
- **Lead sponsor:** Jonathan Brammer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356245, "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07356245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*